In short
Outlook Therapeutics, Inc. (OTLK) has net income up 17.2% to -$62.4M and EPS (Diluted) up 55.9% to $-1.79 year on year. Its gross margin 4.0%. Fisclear flags 4 high-severity risks, led by: Net loss of $62.4M — the company spent more than it earned. Investors should monitor the path to profitability. How we calculate this
Valuation
HealthcareLive · Yahoo Finance52-Week Range
Decision Context
Altman Z-Score indicates financial distress risk. Review debt levels and cash runway before any position sizing decision.
Based on filing period ending Jun 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.75%
Accommodative
10-Year Treasury
4.99%
2026-09-01
Unemployment
4.2%
Near full employment
CPI Index
334.1
2026-08-01
M2 Money Supply
$23.3T
2026-08-01
The Federal Funds rate stands at 3.75% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.99%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 103.1; M2 money supply is $23.3T; CPI index stands at 334.1.
SWOT Analysis — OTLK
Inflationary BoomStrengths
EPS (Diluted): $-1.79 (+55.9% YoY) — Negative EPS — the company recorded a loss on a per-share basis.
Operating Cash Flow: -$51.8M (+24.7% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.
Net Income: -$62.4M (+17.2% YoY) — The company posted a net loss — total expenses exceeded total revenue.
Weaknesses
Total Assets: $18.6M (-35.5% YoY) — Total assets shrank 36% — the balance sheet contracted.
R&D spending is 1923% of revenue — heavy investment in future growth, but also a drag on current profitability.
Opportunities
No clear opportunities identified at this time.
Threats
Net loss of $62.4M — the company spent more than it earned. Investors should monitor the path to profitability.
Negative operating cash flow of $51.8M — the core business consumed more cash than it generated.
Total liabilities are 273% of total assets — the balance sheet is heavily leveraged with limited equity cushion.
Current ratio of 0.38x — short-term liabilities exceed current assets, which could create near-term liquidity pressure.
Quarter-over-Quarter Comparison
2026-03-31 → 2026-06-30| Metric | 2026-03-31 | 2026-06-30 | Change |
|---|---|---|---|
| Revenue | $8M | $1M | ▼82.6% |
| Gross Profit | 57205.00 | 57205.00 | –0.0% |
| Operating Income | $-67M | $-67M | –0.0% |
| Net Income | $-62M | $-62M | –0.0% |
| EPS (diluted) | $-1.79 | $-1.79 | –0.0% |
| Operating CF | $-52M | $-52M | –0.0% |
Risk factor changes vs prior filing
R&D spending is 1923% of revenue — heavy investment in future growth, but also a drag on current profitability.
R&D spending is 334% of revenue — heavy investment in future growth, but also a drag on current profitability.
Year-over-Year Changes
EPS (Diluted)
$-1.79
was $-4.06
Negative EPS — the company recorded a loss on a per-share basis.
Total Assets
$18.6M
was $28.8M
Total assets shrank 36% — the balance sheet contracted.
Operating Cash Flow
-$51.8M
was -$68.8M
Negative operating cash flow — the business consumed more cash than it produced from operations.
Net Income
-$62.4M
was -$75.4M
The company posted a net loss — total expenses exceeded total revenue.
Risk Flags
4 high · 0 medium · 1 low- ⚠ High
Net loss of $62.4M — the company spent more than it earned. Investors should monitor the path to profitability.
- ⚠ High
Negative operating cash flow of $51.8M — the core business consumed more cash than it generated.
- ⚠ High
Total liabilities are 273% of total assets — the balance sheet is heavily leveraged with limited equity cushion.
- ⚠ High
Current ratio of 0.38x — short-term liabilities exceed current assets, which could create near-term liquidity pressure.
- ○ Low
R&D spending is 1923% of revenue — heavy investment in future growth, but also a drag on current profitability.
Technical Signals
Daily closes · 1-year dataOutlook Therapeutics, Inc.: common questions
Is Outlook Therapeutics, Inc. profitable?
No. Outlook Therapeutics, Inc. reported a net loss of $62M in its latest fiscal year (fiscal 2025).
What is Outlook Therapeutics, Inc.'s P/E ratio?
Outlook Therapeutics, Inc. has no meaningful P/E ratio at the moment, because it lost money over the latest year. P/E only works when earnings are positive.
Does Outlook Therapeutics, Inc. pay a dividend?
No dividend is currently expected from Outlook Therapeutics, Inc., according to the latest market data.
What are the main risks for Outlook Therapeutics, Inc.?
Fisclear's checks flag 4 medium- or high-severity risks. The most serious: Net loss of $62.4M — the company spent more than it earned. Investors should monitor the path to profitability.
Answers are generated from the figures in this report (updated 9 Oct 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — OTLK
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade OTLK
Links open broker research pages. Not an endorsement or recommendation.
Research Outlook Therapeutics, Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.